



MASTERCLASS IN SYSTEMIC CANCER THERAPY (MSCT) 2021 AGENDA

DAY 3 - 11TH SEPTEMBER 2021
(SATURDAY)

Time	Topics	Speakers
Plenary 1: Moderator Dr Yong Chen Joyce		
0900-0905	Welcome address	
0905-0930	Personalized medicine in cancer therapeutics: past, present and future <i>Supported by Merck</i>	Ho Kean Fatt Clinical Oncologist, Mt Miriam Cancer Hospital
0930-1000	Biomarkers and Cancer Genomic Profiling <i>Supported by AstraZeneca</i>	Mastura Md Yusof Clinical Oncologist, Pantai Hospital Kuala Lumpur
1000-1015	Q&A	
1015-1030	BREAK	
Plenary 2: Moderator Dr Nur Faizah Muin		
1030-1100	EGFR-targeted therapy <i>Supported by Boehringer Ingelheim</i>	Junie Khoo Yu Yen Clinical Oncologist, Beacon Hospital
1100-1130	ALK/ROS-1 Inhibitor Therapy <i>Supported by Roche</i>	Junie Khoo Yu Yen Clinical Oncologist, Beacon Hospital
1130-1200	Multikinase Inhibitors I <i>Supported by Eisai</i>	Tan Chih Kiang Clinical Oncologist, Tung Shin Hospital
1200-1215	Q&A	
1215-1230	BREAK	
Plenary 3: Moderator Dr Cheong E Von		
1230-1300	BRAF/MEK inhibitors	John Low Clinical Oncologist, Pantai Hospital Kuala Lumpur
1300-1330	HER-2 targeted therapy <i>Supported by Roche</i>	Doris Chow Clinical Oncologist, Mt Miriam Cancer Hospital
1330-1400	CDK4/6, PIK3CAi, AKT and mTOR inhibitors <i>Supported by Pfizer</i>	Senthil Rajappa Medical Oncologist, Hyderabad India
1400-1415	Q&A <i>Supported by Zuellig Pharma</i>	
1415-1430	Closing	

MASTERCLASS IN SYSTEMIC CANCER THERAPY (MSCT) 2021 AGENDA

DAY 4 - 12TH SEPTEMBER 2021
(SUNDAY)

Time	Topics	Speakers
Plenary 4: Moderator Dr Rangasamy Ramachandran		
0900-0930	Somatostatin targeted therapy <i>Supported by Ipsen</i>	David Tai Medical Oncologist, NCCS Singapore
0930-1000	PARP inhibitors	Tan Jing Ying Tira, Medical Oncologist, NCCS Singapore
1000-1030	Immune - checkpoint inhibitors <i>Supported by Roche</i>	Toh Han Chong Medical Oncologist, NCCS Singapore
1030-1100	VEGF Targeted Therapy and Multikinase inhibitors II <i>Supported by Ipsen</i>	Syadwa Abdul Shukor Clinical Oncologist, Hospital Umum Sarawak
1100-1115	Q&A	
1115-1130	BREAK	
Plenary 5: Moderator Dr Vickee Rajeswaran		
1130-1200	Biosimilar : Development and challenges <i>Supported by Duopharma</i>	Chua Hui Ming Pharmacist, National Pharmaceutical Regulatory Agency
1200-1230	Immune-mediated toxicities	Ibtisam Muhamad Nor Clinical Oncologist, Hospital Kuala Lumpur
1230-1300	Other rarer mutations/targets and intervention	Wan Zamaniah Wan Ishak Clinical Oncologist, University Malaya Medical Centre
1300-1315	Q&A	
1315-1330	BREAK	
Plenary 6: Moderator Dr Edmund Chin		
1330-1400	CAR T cell therapy	Gan Gin Gin Haematologist, University Malaya Medical Centre
1400-1430	High dose chemotherapy <i>Supported by BD</i>	Bee Ping Chong Haematologist, University Malaya Medical Centre
1430-1455	Extravasation	Suzila Bt Sulaiman, Oncology Nurse, University Malaya Medical Centre
1455-1510	Q&A	
1510-1530	QUIZ (plenary 7-12), winners and closing	